Clindamycin is a lincosamide antibacterial sold in the U.S. under 11 brand and generic names, for acne vulgaris, actinomycetales infections and bacteroides infections. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Clindesse (application NDA050793). Other clindamycin products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dose is the complete contents of a single pre-filled applicator containing 5 g of Clindesse cream administered once intravaginally at any time of the day. Not for ophthalmic, dermal, or oral use. • For intravaginal use only • A single applicator of cream administered once intravaginally at any time of the day ( 2 ) • Not for ophthalmic, dermal, or oral use
Most common adverse reactions reported in ≥2% of patients and at a higher rate in the Clindesse group than in the placebo group are vaginosis fungal (14%), headache (7%), back pain (5%), constipation (2%), and urinary tract infection (2%) ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Study Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to Clindesse in 368 patients. Clindesse was studied in three clinical studies: placebo-controlled (n=85), active-controlled (n=263), and single-arm (n=20). The population was female, aged 18 to 78, who were diagnosed with bacterial vaginosis. Patient demographics in the trials were 51% Caucasian, 36% Black, 10% Hispanic, and 3% Asian, other or unknown. All patients received 100 mg clindamycin phosphate cream intravaginally in a single dose. Of the 368 women treated with a single dose of Clindesse, 1.6% of the patients discontinued therapy due to adverse reactions. Adverse reactions occurred in 126 of 368 patients (34%) treated with Clindesse and in 32 of 85 patients (38%) treated…
History of hypersensitivity to clindamycin or other lincosamides ( 4.1 ) • History of regional enteritis, ulcerative colitis, or a history of Clostridioides difficile- associated diarrhea ( 4.2 , 5.1 ) 4.1 Hypersensitivity Clindesse is contraindicated in individuals with a history of hypersensitivity to clindamycin or other lincosamides. Reported reactions to other formulations of clindamycin include rashes, urticaria, erythema multiforme, and anaphylactoid reactions [see Adverse Reactions ( 6.2 )] . 4.2 History of Bowel Disease Clindesse is contraindicated in patients with regional enteritis, ulcerative colitis, or a history of Clostridioides difficile -associated diarrhea.
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Prescription | Topical | Generic | $0 | View → | |
| 2 | 70/100 | Prescription | Topical | Generic |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| G;144 | 300 mg | blue | capsule | — |
| M;41 | 150 mg | green, blue | capsule | — |
| RX692;RX692 | 150 mg | blue, green | capsule | — |
| RX693;RX693 | 300 mg | blue, blue | capsule | — |
| G;143 | 150 mg | blue, green | capsule | — |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Clindamycin Phosphate USP
Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.
SUN PHARMACEUTICAL INDUSTRIES INC · Nov 26, 2025
Clindamycin HCl Capsule
CGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.
RemedyRePack Inc. · Apr 22, 2025
Clindamycin Hydrochloride Capsules
cGMP Deviations
Preferred Pharmaceuticals, Inc. · Apr 18, 2025
Clindamycin HCl
CGMP Deviations
RemedyRepack Inc. · Mar 24, 2025
Clindamycin Hydrochloride Capsules
CGMP Deviations
Glenmark Pharmaceuticals Inc., USA · Mar 13, 2025
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
No formal drug interaction studies have been conducted for Clindesse. Neuromuscular blocking agents: Enhanced action of neuromuscular blocking agents can occur; use with caution ( 7.1 ) 7.1 Neuromuscular Blocking Agents Orally or intravenously administered clindamycin has neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
| $0 |
| View → |
| 3 | 56/100 | Prescription | Topical | Generic | $0 | View → |
| 4 | 56/100 | Prescription | Capsule | Generic | $0 | View → |
| 5 | 56/100 | Prescription | Injectable | Generic | $0 | View → |
| 6 | 56/100 | Prescription | Topical | Generic | $0 | View → |
| 7 | 38/100 | Prescription | Injectable | Generic | $0 | View → |
| 8 | Not yet rated | Prescription | Topical | Generic | $0 | View → |
| 9 | Not yet rated | Prescription | Capsule | Generic | $0 | View → |
| 10 | Not yet rated | Prescription | Topical | Generic | $0 | View → |